Drug Database
IN

influenza vaccine (Ultravac / Ultravak)

✓ Approved

Microgen · 疫苗 · 疫苗

什么是 influenza vaccine?

influenza vaccine 是一种疫苗,由Microgen研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。

药物档案

商品名Ultravac, Ultravak
公司Microgen
药物类别疫苗, 大分子
给药途径Inhaled
状态Approved

相关研究文献

PubMedInfluenza and other respiratory viruses2026-11-17

A Canadian Laboratory-Based Retrospective of the 2024/2025 Influenza Season: Monitoring the Impacts of Influenza Evolution on Viral Antigenicity and Antiviral Susceptibility.

Ranadheera Charlene C, Gao Ruimin R, Buchanan Cody C, Frost Jasmine J et al.

Seasonal influenza affects thousands of Canadians each year and places significant strain on workplaces and the health systems. Robust laboratory-based surveillance is essential to monitor viral evolution and evaluate the suitability of medical countermeasures. The Canadian Influenza Surveillance Program characterizes circulating influenza viruses to determine genetic clades, monitor evolutionary trends, assess antigenicity and vaccine strain relatedness, and evaluate susceptibility to neuraminidase inhibitors. Methods include whole genome sequencing, hemagglutination inhibition assays, and neuraminidase inhibition assays. From September 1, 2024 to August 31, 2025, the program antigenically characterized 1563 influenza isolates identified and submitted by Canadian laboratories. Of these, 99.4% of influenza A/H1N1, 86.6% of influenza A/H3N2, and 100% of influenza B isolates were antigenically related to their respective component of the 2024-2025 Northern Hemisphere vaccine. Genetic analysis of influenza A/H3N2 isolates identified three distinct mutation clustering patterns associated with reduced antigenic reactivity to the vaccine strain. Additionally, 1567 influenza viruses underwent antiviral susceptibility testing. Eleven influenza A/H1N1 isolates showed reduced inhibition to oseltamivir and two to zanamivir, all containing known resistance-associated markers. These findings highlight the importance of comprehensive virological assessment, integrating genotypic and phenotypic data, to inform annual vaccine strain selection and support clinical decision-making.

PMID 43039871
阅读全文 →
PubMedThe Journal of infectious diseases2026-11-17

A prospective, comparative cohort analysis of influenza antibody waning in Michigan and Hong Kong during periods of low influenza circulation.

Yang Yanyupei Y, Smith Matthew M, Ho Faith F, Truscon Rachel R et al.

Reduced influenza transmission during the COVID-19 pandemic prompted concern about waning of population immunity that could lead to subsequent surges in circulation. We compared longitudinal influenza antibody titers in Michigan and Hong Kong, two regions with reduced influenza transmission during the COVID-19 pandemic. In two prospective cohort studies (HIVE, Michigan; EPI-HK, Hong Kong), we analyzed longitudinal serum samples collected from 2020 through 2023 from participants without influenza infection or vaccination. Sera were tested using hemagglutination inhibition assays (HAI) and microneutralization (MN) against vaccine strains. Two-year fold changes in titers were estimated using multivariable power-law models adjusted for age and baseline titer. We analyzed 173 sera from 57 HIVE participants and 259 sera from 60 EPI-HK participants. Initial HAI geometric mean titers ranged from 12.3-123.4 in HIVE and 6.3-40.9 in EPI-HK. Among those with >1:40 baseline titers in HIVE, fold-change estimates indicated waning for H1N1 strains, including A/Brisbane (0.70 [95% CI: 0.56,0.86]), A/Idaho (0.40 [0.32,0.50]), and A/Michigan (0.43 [0.34,0.52]), while H3N2 and influenza B showed minimal or no waning. In EPI-HK, fold-change estimates demonstrated heterogeneous patterns by strain for H1N1, and waning for selected H3N2 strains, including A/Cambodia (0.44 [0.29,0.65]) and A/Singapore (0.48 [0.33,0.69]). MN results were consistent with HAI findings. Influenza antibody responses during the pandemic showed heterogeneous, strain-specific changes rather than uniform decline. These findings suggest that population immunity was maintained for many strains despite reduced viral circulation, with waning occurring in particular strains and varying by population.

PMID 43043347
阅读全文 →
PubMedNature communications2026-11-17

Developing and benchmarking one health genomic surveillance tools for influenza A virus in wastewater.

Jiang Minxi M, Wang Audrey L W ALW, Thissen James B JB, Nelson Kara L KL et al.

Influenza A viruses (IAV) remain a persistent One Health threat, and whole-genome sequencing from wastewater offers a promising surveillance tool. However, IAV is at low abundance in wastewater, making it difficult to sequence. We benchmark four targeted enrichment methods suited for multi-subtype whole-genome IAV sequencing including custom and off-the-shelf methods. Our custom HA tiled-amplicon panel is sensitive, fast, and cost-effective, making it suitable for monitoring low-abundance seasonal variants of known subtypes, although its reliance on conserved and intact primer-binding sites limits primer design to fewer subtypes. A published universal amplicon method targets all IAV subtypes but performs poorly in wastewater due to its reliance on intact genome segments. Meanwhile, probe-capture methods are resilient to RNA degradation. In real wastewater samples, our custom probe panel recovers whole-genome signals from circulating H1N1, H3N2, H5N1, including validated H5N1 2.3.4.4b reads in samples where dPCR detection is limited. However, probe-capture is generally more costly and labor-intensive than amplicon methods. Across all four sequencing methods, two wastewater matrices, and most spike-in and endogenous virus targets, ultrafiltration-based virus concentration consistently outperforms large-volume direct extraction. Together, these benchmarking comparisons and custom panels provide needed information for implementing IAV genomic sequencing in routine wastewater surveillance.

PMID 43039891
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedJournal of cheminformatics2026-11-17

MoActiPred: an AI-Based bioactivity prediction model applied to the development of influenza neuraminidase inhibitors.

Zhang Zeqi Z, Ye Jiqing J, Zou Qingyu Q, Ji Chenyi C et al.

Accurate prediction of small-molecule bioactivity is critical for accelerating drug discovery. Here, we report MoActiPred, a multimodal AI framework that integrates 2D molecular graphs, physicochemical descriptors, and 3D E (3)-equivariant geometric representations. Using a curated ChEMBL-derived influenza virus neuraminidase (NA) inhibitor dataset (1245 compounds; IC50 threshold 20 nM), MoActiPred showed the strongest overall performance among the evaluated methods, including traditional machine-learning models (Random Forest, SVM, and XGBoost), SMILES-based language models (ChemBERTa, ChemFM, and PolyBERT), and graph-based baselines (MolCLR and SEGNN). On the public test set, MoActiPred obtained an accuracy of 0.952, MCC of 0.797, and F1 score of 0.898, while retaining high average precision, supporting the value of combining 2D and 3D representations. To evaluate its practical utility, MoActiPred was applied prospectively to 26 oseltamivir analogues designed, experimentally synthesised and evaluated against influenza A (H3N2) NA. The model correctly predicted 6 of 7 high-activity compounds (IC50 < 20 nM) and 18 of 19 inactive or weakly active derivatives, yielding 92.3% accuracy. Enzymatic assays showed that most derivatives were active, with 5b and 5f emerging as the most potent inhibitors (IC50 4.31 and 6.49 nM, respectively). In MDCK.2 cell-based assays, 5b and 5f exhibited strong H3N2-selective antiviral activity, with EC₅₀ values of 0.72 nM and 3.04 nM, respectively, and no detectable cytotoxicity (CC50 > 100 μM). Docking, MD simulations, and water-map analyses indicated that the oseltamivir core of 5b occupies the conserved active site while its N-substituent engages the 150- and 430-cavities, with solvation-driven binding particularly favouring N2. These results support that MoActiPred's utility in drug discovery research and identify 5b as a promising lead for further optimisation against influenza A (H3N2).Scientific contributionMoActiPred advances bioactivity prediction by integrating 2D molecular graphs, physicochemical descriptors, and 3D E (3)-equivariant geometric representations within a single multimodal framework. Compared with conventional machine-learning models, SMILES-based language models, and graph-based baselines, MoActiPred achieved stronger classification performance on the curated and public neuraminidase inhibitor datasets, demonstrating the value of combined 2D/3D molecular representation learning. Its prospective utility was further supported by in-house synthesis of a focused oseltamivir-analogue series followed by enzymatic and cell-based biological activity testing.

PMID 43040379
阅读全文 →
PubMedMicrobial cell factories2026-11-17

Construction and immunogenicity evaluation of recombinant Bacillus subtilis expressing VP8 protein of porcine rotavirus.

Wang Zhikui Z, Yan Xinping X, Wang Xu X, Yue Xiaoxue X et al.

Porcine rotavirus (PoRV), an enteric infectious virus, is a major cause of neonatal diarrhea in piglets, resulting in significant economic losses to the global swine industry. In this study, the cholera toxin B subunit (CTB) was utilized as a molecular adjuvant to construct recombinant Bacillus subtilis (B. subtilis) strains expressing VP8 proteins and CTB-VP8 fusion proteins derived from the PoRV genotypes P[7], P[13], and P[23]. The recombinant strains expressing PoRV proteins from different genotypes were combined and orally administered to mice, and their immunogenicity and probiotic functions were evaluated. The results demonstrated that the recombinant B. subtilis significantly increased serum-specific IgG and fecal-specific sIgA antibodies levels (P < 0.001), indicating that the recombinant strains induced both humoral and mucosal antibody responses in mice. Notably, the CTB-fused strains elicited higher titers of IgG and sIgA. Furthermore, the recombinant strains significantly elevated the expression levels of cytokines, including IFN-γ, IL-2, and IL-4, in both serum and intestinal mucosa (P < 0.01), suggesting a Th1/Th2-biased immune response at the cytokine level. In addition, administration of recombinant B. subtilis increased villus height and the villus height-to-crypt depth ratio while reducing crypt depth, showing a tendency to improve intestinal morphology. This study addresses the limitations associated with insufficient mucosal immune activation by conventional injectable approaches and the absence of cross-protection among different genotypes of PoRV, thereby providing a theoretical foundation for the development of an oral trivalent live-vector vaccine.

PMID 43040377
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多influenza vaccine